A randomized, placebo-controlled study investigating the nicotinic 7 agonist, RG3487, for cognitive deficits in schizophrenia

Neuropsychopharmacology

Volumn 39, Issue 7, 2014, Pages 1568-1577

  Umbricht, Daniel ^a   Keefe, Richard S E ^b   Murray, Stephen ^c   Lowe, David A ^c   Porter, Richard ^a   Garibaldi, George ^a   Santarelli, Luca ^a  

^a Preclinical Neurosciences   (Switzerland)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c Memory Pharmaceuticals Corporation   (United States)

Author keywords

cognition; randomized controlled study; schizophrenia; 7 nicotinic receptor

Indexed keywords

ARIPIPRAZOLE; BUNGAROTOXIN RECEPTOR; CREATINE KINASE; NICOTINIC AGENT; PALIPERIDONE; PLACEBO; RG 3487; RISPERIDONE; UNCLASSIFIED DRUG; BICYCLO COMPOUND; INDAZOLE DERIVATIVE; N-((3S)-1-AZABICYCLO(2.2.2)OCT-3-YL)-1H-INDAZOLE-3-CARBOXAMIDE HYDROCHLORIDE; NEUROLEPTIC AGENT;

ADULT; ANXIETY; ARTHRALGIA; ARTICLE; BACKACHE; BEHAVIOR DISORDER; COGNITIVE DEFECT; COGNITIVE IMPAIRMENT ASSOCIATED SCHIZOPHRENIA; CONNECTIVE TISSUE DISEASE; CONSTIPATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; FEMALE; FOLLOW UP; GASTROINTESTINAL DISEASE; HEART DISEASE; HEMATOLOGIC DISEASE; HUMAN; INFECTION; INFESTATION; INSOMNIA; LYMPHATIC SYSTEM DISEASE; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MUSCULOSKELETAL DISEASE; NAUSEA; NEGATIVE SYNDROME; NOSE OBSTRUCTION; POST HOC ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SINUSITIS; SOMNOLENCE; SUICIDAL IDEATION; SYMPTOM ASSESSMENT; TOOTH PAIN; UPPER RESPIRATORY TRACT INFECTION; XEROSTOMIA; ADOLESCENT; CLINICAL TRIAL; COGNITION DISORDERS; COMPLICATION; MIDDLE AGED; MULTICENTER STUDY; NEUROPSYCHOLOGICAL TEST; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; BICYCLO COMPOUNDS; COGNITION DISORDERS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INDAZOLES; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; NICOTINIC AGONISTS; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84900558088     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2014.17     Document Type: Article

References (34)

1. Adler LE, Olincy A, Waldo M, Harris JG, Griffith J, Stevens K et al (1998). Schizophrenia, sensory gating, and nicotinic receptors. Schizophr Bull 24: 189-202.
2. American Psychiatric Association (2000). Diagnostic and Statistical Manual of Mental DisorDers. 4th edn text rev. Washington, DC.
3. Buchanan RW, Conley RR, Dickinson D, Ball MP, Feldman S, Gold JM et al (2008). Galantamine for the treatment of cognitive impairments in people with schizophrenia. Am J Psychiatry 165: 82-89.
4. Buchanan RW, Davis M, Goff D, Green MF, Keefe RS, Leon AC et al (2005). A summary of the FDA-NIMH-MATRICS workshop on clinical trial Design for neurocognitive drugs for schizophrenia. Schizoph r Bull 31: 5-19.
5. Buchanan RW, Keefe RS, Lieberman JA, Barch DM, Csernansky JG, Goff DC et al (2011). A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with s chizophrenia. Biol Psychiatry 69: 442-449.
6. Freedman R, Olincy A, Buchanan RW, Harris JG, Gold JM, Johnson L et al (2008). Initial phase 2 trial of a nicotinic agonist in schizophrenia. Am J Psychiatry 165: 1040-1047.
7. Geerts H (2012). alpha7 Nicotinic receptor modulators for cognitive Deficits in schizophrenia and Alzheimer?s disease. Expert Opin Investig Drugs 21: 59-65.
8. G enevsky A, Garrett CT, AlexanDer PP, Vinogradov S (2010). Cognitive training in schizophrenia: A neuroscience-based approach. Dialogues Clin Neurosci 12: 416-421.
9. Gotti C, Clementi F (2004). Ne uronal nicotinic receptors: From structure to pathology. Prog Neurobiol 74: 363-396.
10. Gray JA, Roth BL (2007). Molecular targets for treating cognitive dysfunction in schizophrenia. Schizophr Bull 33: 1100-1119.
11. Hilt D, Meltzer H, Gawry M, Ward S, Dgetluck N, Bhuvaneswaran C et al (2011). EVP-6124, an alpha-7 nicotinic partial agonist, produces positive effects on cognition, clinical function, and nega tive symptoms in patients with chronic schizophrenia on stable antipsychotic therapy. Abstract accepted for presentation at the 50th Annual Meeting of the American College of Neuropsychopharmacology: Waikoloa, Hawaii, 4-8 December www.acnp.org/ annualmeeting/programbooks.aspx.
12. Javitt DC, Buchanan RW, Keefe RSE, Kern R, McMahon RP, Green MF et al (2012). Effect of the neuroprotective peptiDe davunetiDe (AL-108) on cognition and functional capacity in sc hizophrenia. Schizophr Res 136: 25-31.
13. Keefe RSE (2012). Issues in the Assessment of Cognition and Functioning in Clinical Trials. ECNP Annual Meeting: Vienna, Austria.
14. Keefe RS, Buchanan RW, MarDer SR, Schooler NR, Dugar A, Zivkov M et al (2013). Clinical trials of potential cognitiveenhancing drugs in schizophrenia: what have we learned so far Schizophr Bull 39: 417-435 .
15. Keefe RS, Fox KH, Harvey PD, Cucchiaro J, Siu C, Loebel A (2011). Characteristics of the MATRICS Consensus Cognitive Battery in a 29-site antipsychotic schizophrenia clinical trial. Schizophr Res 125: 161-168.
16. Keefe RS, Malhotra AK, Meltzer HY, Kane JM, Buchanan RW, Murthy A et al (2008). Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorDer: Significant placebo/ practice effects in a 12-week, randomized, double-blind, placebo-controlled trial. Neuropsychopharmacology 33: 1217-1228.
17. Kern RS, Nuechterlein KH, Green MF, BaaDe LE, Fenton WS, Gold JM et al (2 008). The MATRICS Consensus Cognitive Battery, part 2: Co-norming and standardization. Am J Psychiatry 165: 214-220.
18. Kraemer HC, Kupfer DJ (2006). Size of treatment effects and their importance to clinical research and practice. Biol Psychiatry 59: 990-996.
19. Kucinski AJ, Stachowiak MK, Wersinger SR, Lippiello PM, Bencherif M (2011). Alpha7 neuronal nicotinic receptors as targets for novel therapies to tre at multiple domains of schizophrenia. Curr Pharm Biotechnol 12: 437-448.
20. Lieberman JA,Dunbar G,Segreti AC,Girgis RR,Seoane F,Beaver JS,et al,2013, A randomized exploratory trial of an alp ha-7 nicotinic receptor agonist (TC-5619) for cognitive enhancement in schizophrenia, Neuropsychopharmacology, 38, 968-975.
21. LinDenmayer JP, Khan A (2011). Galantamine augmentation of long-acting injectable risperidone for cognitive impairments in chronic schizophrenia. Schizophr Res 125: 267-277.
22. MarDer SR, Davis JM, Chouinard G (1997). The effects of risperidone on the five dimensions of schizophrenia Derived by fact or analysis: Combined results of the North American trials. J Clin Psychiatry 58: 538-546.
23. Morosini PL, Magliano L, Brambilla L, Ugolini S, Pioli R (2000). Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning. Acta Psychiatr Scand 101: 323-329.
24. Nuechterlein KH, Green MF, Kern RS, BaaDe LE, Barch DM, Cohen JD et al (2008). The MATRICS Consensus Cognitive Battery, part 1: Test selection, reliability, and validity. Am J Psychiatry 165: 203-213.
25. Olincy A, Harris JG, Johnson LL, P enDer V, Kongs S, Allensworth D et al (2006). Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia. Arch Gen Psychiatry 63: 630-638.
26. Patterson TL, Goldman S, McKibbin CL, H ughs T, Jeste DV (2001). UCSD Performance-Based Skills Assessment: Development of a new measure of everyday functioning for severely mentally ill adults. Schizophr Bull 27: 235-245.
27. Prickaerts J, van Goethem NP, Chesworth R, Shapiro G, Boess FG, Methfessel C et al (2012). EVP-6124, a novel and selective alpha7 nicotinic acetylcholine receptor partial agonist, improves memory performance by potenti ating the acetylcholine response of alpha7 nicotinic acetylcholine receptors. Neuropharmacology 62: 1099-1110.
28. Severance EG, Yolken RH (2008). Novel alpha7 nicotinic receptor isoforms and Deficient cholinergic transcription in schizophrenia. Genes Brain Behav 7: 37-45.
29. Singh J, Kour K, Jayaram MB (2012). Acetylcholinesterase inhibitors for schizophrenia. Cochrane Database Syst Rev 1: CD007967.
30. Wallace TL, Callahan PM, Tehim A, Bertrand D, Tombaugh G, Wang S et al (2011). RG3487, a novel nicotinic alpha7 receptor partial agonist, improves cognition and sensorimotor gating in roDents. J Pharmacol Exp Ther 336: 242-253.
31. Wang HY, Stucky A, Liu J, Shen C, Trocme-Thibierge C, Morain P (2009). Dissociating beta-amyloid from alpha 7 nicotinic acetylcholine receptor by a novel therapeutic agent, S 24795, normalizes alpha 7 nicotinic acetylcholine and NMDA receptor function in Alzheimer?s disease brain. J Neurosci 29: 10961-10973.
32. Wesnes K, Brooker H, Evins AE (2010). A study comparing the MATRICS battery with the CDR system in schizophrenia. Schizophr Res 117: 416.
33. Zhang R, White NA, Soti FS, Kem WR, Machu TK (2006a ). Nterminal domains in mouse and human 5-hydroxytryptamine3A receptors confer partial agonist and antagonist properties to benzyliDene analogs of anabaseine. J Pharmacol Exp Ther 317: 1276-1284.
34. Zhang ZJ, Kang WH, Li Q, Wang XY, Yao SM, Ma AQ (2006b ). Beneficial effects of ondansetron as an adjunct to haloperidol for chronic, treatment-resistant schizophrenia: A double-blind, randomized, placebo-controlled study. Schizophr Res 88: 102-110.